Rigel Pharmaceuticals. has filed a patent for a pyrazole compound that can inhibit an IRAK protein and treat associated diseases. The compound can be formulated with a carrier like a polymer or as a spray-dried formulation. Claim 1 specifies the compound’s chemical structure as sodium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen phosphate. GlobalData’s report on Rigel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Rigel Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Rigel Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Rigel Pharmaceuticals's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Pyrazole compound for inhibiting irak protein in subjects

Source: United States Patent and Trademark Office (USPTO). Credit: Rigel Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230399326A1) discloses a compound that shows promise in treating a wide range of diseases and conditions for which an IRAK inhibitor is indicated. The compound, sodium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen phosphate, is proposed for use in treating autoimmune diseases, inflammatory disorders, cardiovascular diseases, neurodegenerative disorders, cancer, transplantation, and various other conditions. The patent also covers a composition comprising the compound and a pharmaceutically acceptable excipient.

Furthermore, the patent outlines specific methods for treating diseases such as rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, and various types of cancers, including solid tumors, lymphoid neoplasms, and hematological malignancies. The method involves administering the compound or composition to a subject in need of treatment, either alone or in combination with a second therapeutic agent such as an analgesic, antibiotic, anticoagulant, antibody, anti-inflammatory agent, or antiviral. The compound shows potential in addressing drug-resistant malignancies, hyperproliferative skin disorders, and inflammatory skin diseases, offering a broad spectrum of therapeutic applications for various medical conditions.

To know more about GlobalData’s detailed insights on Rigel Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies